Aileron Therapeutics is a clinical stage company discovering and developing novel medicines for the treatment of cancer and for cancer supportive care by targeting high value and historically undruggable intracellular targets using a proprietary platform of stabilized cell-permeating peptides. Our lead product candidate, ALRN-6924, is a first-in-class dual MDM2/MDMX inhibitor that has been tested in hematologic cancers and is currently being evaluated in a Phase 2 clinical trial in combination with Pfizerâs palbociclib (IbranceÂŽ) for the treatment of MDM2-amplified advanced solid cancers, and in an upcoming Phase 1b/2 clinical trial to evaluate ALRN-6924 as a myelopreservative agent to protect against chemotherapy-induced toxicities. Emerging ALRN-6924 clinical and substantial preclinical data support its use across multiple cancer types as a combination therapy with targeted agents, chemotherapies, and immuno-oncology drugs. Aileron Therapeutics is exploring collaboration opportunities regarding ALRN-6924 and for its research in areas such as targeted protein degradation, HIF1-Îą, and the Bcl-2 family of cancer targets. Source
No articles found.
miRagen Therapeutics, Inc., is a clinical stage biopharmaceutical company discover...
miRagen Therapeutics, Inc., is a clinical stage...
Neuronetics, Inc. is focused on designing, developing, and marketing products that...
Neuronetics, Inc. is focused on designing, deve...
Rigel Pharmaceuticals, Inc. is a biotechnology company dedicated to discovering, d...
Rigel Pharmaceuticals, Inc. is a biotechnology ...
Terumo Corporation is a manufacturer and supplier of pharmaceuticals and medical t...
Terumo Corporation is a manufacturer and suppli...
Mylan is a global pharmaceutical company committed to setting new standards in hea...
Mylan is a global pharmaceutical company commit...
KalVista is a pharmaceutical company focused on the discovery, development and com...
KalVista is a pharmaceutical company focused on...
At Affimed, we are committed to improving outcomes for patients with cancer. Our s...
At Affimed, we are committed to improving outco...
Join the National Investor Network and get the latest information with your interests in mind.